Oncolytic Microorganism Prime-Boost Regimens for Tumor-Targeted Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies struggle to induce a robust immune response specifically targeting cancer cells.
Innovation Solution
A heterologous prime-boost regimen using recombinant oncolytic microorganisms that selectively replicate in tumor cells and not in non-tumor cells, enhancing or eliciting an immune response to tumor proteins not coded by these microorganisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies are used, then treatment is administered, but robust immune response specifically targeting cancer cells is not achieved
Solution Approach 1:
The patent divides the immunotherapy into two distinct segments: a prime microorganism that initiates immune response and a boost microorganism that enhances it. This segmentation allows each microorganism to be optimized for specific functions, with the prime providing initial antigen exposure and the boost providing enhanced immune activation, thereby achieving both reliability and productivity in cancer targeting
Solution Approach 2:
The patent employs parameter changes by using heterologous microorganisms with different biological properties and antigen profiles. The prime and boost microorganisms are selected to have complementary characteristics, changing the immunogenic parameters through sequential administration to achieve robust and specific anti-tumor immune responses that neither microorganism could achieve alone
2Manufacturing precision
If oncolytic microorganisms replicate selectively in tumor cells, then tumor targeting is improved, but immune response to non-coded tumor proteins is insufficient
Solution Approach 1:
The patent applies universality by designing a heterologous prime-boost regimen where two different microorganisms work together to achieve multiple immune objectives. The prime microorganism provides tumor-specific targeting while the boost microorganism expands immune response breadth to include tumor proteins not coded by the prime, creating a multi-functional system that addresses both selectivity and response breadth requirements
Data Source
AI summary
Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.